Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection

NCT04366245 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

72

Enrollment

OTHER

Sponsor class

Conditions

SARS-CoV 2

Interventions

BIOLOGICAL: Hyperimmune plasma
DRUG: Standard of care for SARS-CoV-2 infection

Sponsor

Andalusian Network for Design and Translation of Advanced Therapies